Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells

Omalizumab (OmAb) is a humanized anti-IgE antibody approved for the treatment of chronic spontaneous urticaria (CSU). OmAb’s mechanism of action is known to include actions on free IgE and on pre-bound IgE. However, OmAb is equally and rapidly effective against autoimmune and non-autoimmune urticari...

Descripción completa

Detalles Bibliográficos
Autores principales: Serrano-Candelas, Eva, Martínez-Aranguren, Rubén, Vega, Olga, Gastaminza, Gabriel, Bartra, Joan, Audicana, Maria Teresa, Núñez-Córdoba, Jorge M., Algorta, Jaime, Valero, Antonio, Martin, Margarita, Ferrer, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566209/
https://www.ncbi.nlm.nih.gov/pubmed/28827590
http://dx.doi.org/10.1038/s41598-017-09361-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566209/
https://www.ncbi.nlm.nih.gov/pubmed/28827590
http://dx.doi.org/10.1038/s41598-017-09361-4

Ejemplares similares